Logo image of ISRL

ISRAEL ACQUISITIONS CORP-A (ISRL) Stock Fundamental Analysis

NASDAQ:ISRL - Nasdaq - KYG496671010 - Common Stock - Currency: USD

11.4  +0.06 (+0.53%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ISRL. ISRL was compared to 0 industry peers in the Unkown industry. The financial health of ISRL is average, but there are quite some concerns on its profitability. ISRL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ISRL had positive earnings in the past year.
ISRL had a positive operating cash flow in the past year.
ISRL Yearly Net Income VS EBIT VS OCF VS FCFISRL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 2M 4M 6M

1.2 Ratios

Industry RankSector Rank
ROA 4.72%
ROE 5.13%
ROIC N/A
ROA(3y)-6.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ISRL Yearly ROA, ROE, ROICISRL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 50 -50 100

1.3 Margins

ISRL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ISRL Yearly Profit, Operating, Gross MarginsISRL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

ISRL has more shares outstanding than it did 1 year ago.
ISRL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ISRL Yearly Shares OutstandingISRL Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M 25M
ISRL Yearly Total Debt VS Total AssetsISRL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M

2.2 Solvency

An Altman-Z score of 7.64 indicates that ISRL is not in any danger for bankruptcy at the moment.
The Debt to FCF ratio of ISRL is 0.22, which is an excellent value as it means it would take ISRL, only 0.22 years of fcf income to pay off all of its debts.
ISRL has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Although ISRL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.22
Altman-Z 7.64
ROIC/WACCN/A
WACCN/A
ISRL Yearly LT Debt VS Equity VS FCFISRL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M

2.3 Liquidity

ISRL has a Current Ratio of 12.53. This indicates that ISRL is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 12.53 indicates that ISRL has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 12.53
Quick Ratio 12.53
ISRL Yearly Current Assets VS Current LiabilitesISRL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.86% over the past year.
EPS 1Y (TTM)11.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ISRL Yearly Revenue VS EstimatesISRL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023
ISRL Yearly EPS VS EstimatesISRL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 45.60 indicates a quite expensive valuation of ISRL.
The average S&P500 Price/Earnings ratio is at 29.63. ISRL is valued rather expensively when compared to this.
Industry RankSector Rank
PE 45.6
Fwd PE N/A
ISRL Price Earnings VS Forward Price EarningsISRL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 25.99
EV/EBITDA N/A
ISRL Per share dataISRL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ISRL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ISRAEL ACQUISITIONS CORP-A

NASDAQ:ISRL (2/20/2025, 8:00:01 PM)

11.4

+0.06 (+0.53%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners334.2%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap72.39M
Analysts0
Price TargetN/A
Short Float %2.01%
Short Ratio0.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 45.6
Fwd PE N/A
P/S N/A
P/FCF 25.99
P/OCF 25.99
P/B 0.96
P/tB 0.96
EV/EBITDA N/A
EPS(TTM)0.25
EY2.19%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.44
FCFY3.85%
OCF(TTM)0.44
OCFY3.85%
SpS0
BVpS11.82
TBVpS11.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.72%
ROE 5.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-6.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.22
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 72.35%
Current Ratio 12.53
Quick Ratio 12.53
Altman-Z 7.64
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.73%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-7892.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7892.27%
OCF growth 3YN/A
OCF growth 5YN/A